Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2010 2
2011 3
2012 4
2013 4
2014 5
2015 11
2016 5
2017 2
2018 1
2019 1
2020 4
2021 7
2022 8
2023 5
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Results by year

Filters applied: . Clear all
Page 1
Intraocular Pressure-Related Events After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Report 16 on a Secondary Analysis of a Randomized Clinical Trial.
Aref AA, Scott IU, VanVeldhuisen PC, King J, Ip MS, Blodi BA, Oden NL; Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Investigator Group. Aref AA, et al. JAMA Ophthalmol. 2021 Dec 1;139(12):1285-1291. doi: 10.1001/jamaophthalmol.2021.4395. JAMA Ophthalmol. 2021. PMID: 34709363 Free PMC article. Clinical Trial.
Baseline Characteristics and Outcomes After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema in Participants With Hemiretinal Vein Occlusion Compared With Participants With Central Retinal Vein Occlusion: Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Report 18.
Scott IU, Oden NL, VanVeldhuisen PC, Ip MS, Blodi BA; SCORE2 Study Investigator Group. Scott IU, et al. JAMA Ophthalmol. 2022 May 1;140(5):458-464. doi: 10.1001/jamaophthalmol.2022.0352. JAMA Ophthalmol. 2022. PMID: 35323843 Free PMC article. Clinical Trial.
Prediction for 2-Year Vision Outcomes Using Early Morphologic and Functional Responses in the Comparison of Age-related Macular Degeneration Treatments Trials.
Xue K, Hua P, Maguire MG, Daniel E, Jaffe GJ, Grunwald JE, Ying GS; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group. Xue K, et al. Ophthalmol Retina. 2023 Jul;7(7):564-572. doi: 10.1016/j.oret.2023.02.008. Epub 2023 Feb 19. Ophthalmol Retina. 2023. PMID: 36803692 Clinical Trial.
Environmental metal exposures and kidney function of Guatemalan sugarcane workers.
Butler-Dawson J, James KA, Krisher L, Jaramillo D, Dally M, Neumann N, Pilloni D, Cruz A, Asensio C, Johnson RJ, Adgate J, Newman LS. Butler-Dawson J, et al. Among authors: jaramillo d. J Expo Sci Environ Epidemiol. 2022 May;32(3):461-471. doi: 10.1038/s41370-021-00292-x. Epub 2021 Feb 18. J Expo Sci Environ Epidemiol. 2022. PMID: 33603096 Free PMC article.
Sugarcane Workweek Study: Mechanisms Underlying Daily Changes in Creatinine.
Dally M, Sorensen CJ, Butler-Dawson J, Griffin BR, Johnson RJ, Krisher L, Jaramillo D, Asensio C, Newman LS. Dally M, et al. Among authors: jaramillo d. Kidney Int Rep. 2021 Aug 27;6(12):3083-3086. doi: 10.1016/j.ekir.2021.08.014. eCollection 2021 Dec. Kidney Int Rep. 2021. PMID: 34901578 Free PMC article. No abstract available.
International Total Worker Health: Applicability to Agribusiness in Latin America.
Jaramillo D, Krisher L, Schwatka NV, Tenney L, Fisher GG, Clancy RL, Shore E, Asensio C, Tetreau S, Castrillo ME, Amenabar I, Cruz A, Pilloni D, Zamora ME, Butler-Dawson J, Dally M, Newman LS. Jaramillo D, et al. Int J Environ Res Public Health. 2021 Feb 25;18(5):2252. doi: 10.3390/ijerph18052252. Int J Environ Res Public Health. 2021. PMID: 33668716 Free PMC article.
58 results